Skip to content
DraconiticResearch
Search Sources API
190,839 studies31 sourcesUpdated 33 min ago
Peer-reviewedCC BY 4.0Cancers

Management Strategies for Cutaneous Adverse Events Caused by Kinase Inhibitors in Oncology: A Systematic Review and Meta-Analysis

  • Renáta Árok1,2,3
  • Fanni Adél Meznerics2,3
  • Andrea Lancz2,3,4
  • Anna Sára Lengyel2,3,5
  • Anna Walter5
  • Péter Hegyi2,6,7
  • András Bánvölgyi2,3
  • Norbert Kiss2,3
7 affiliations
  1. 1Department of Pharmacy, Budapest Bajcsy-Zsilinszky Hospital and Clinic, 1106 Budapest, Hungary
  2. 2Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary
  3. 3Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, 1085 Budapest, Hungary
  4. 4Department of Internal Medicine, Markusovszky University Teaching Hospital, 9700 Szombathely, Hungary
  5. 5HCEMM-SU Translational Dermatology Research Group, Semmelweis University, 1094 Budapest, Hungary
  6. 6Institute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary
  7. 7Institute of Pancreatic Diseases, Semmelweis University, 1083 Budapest, Hungary
Read full textPDFDOICite

Abstract

Background: The use of targeted therapies in oncology has increased significantly, but associated cutaneous adverse events often impair quality of life and adherence. Despite numerous available interventions, there is no unified protocol, and many patients discontinue therapy due to adverse events. This systematic review and meta-analysis aimed to evaluate preventive and reactive interventions for cutaneous adverse events in adult cancer patients receiving kinase inhibitors. Methods: A search was performed in MEDLINE (via PubMed), EMBASE, and CENTRAL (The Cochrane Central Register of Controlled Trials), using predefined search terms. Outcomes were incidence, severity of cutaneous adverse events (grades 1–4 and 3–4), quality of life and adherence to oncologic therapy. Results: After screening 35,072 records, 9 studies (1853 patients, per protocol) met the inclusion criteria for the meta-analysis, while 52 were included in the systematic review. Preventive topical agents significantly reduced the incidence of grade 1–4 cutaneous adverse events (OR, 0.55; 95% CI, 0.38–0.80; p = 0.012; I2 = 16%), whereas systemic interventions showed no significant benefit in this category. Conversely, for grade 3–4 events, systemic interventions were associated with a significantly reduced incidence (OR, 0.24; 95% CI, 0.14–0.41; p = 0.002, I2 = 0%), while topical agents had no significant effect. For reactive interventions, no consistent evidence of effectiveness was found, with high heterogeneity and a limited number of studies. Conclusions: In patients receiving kinase inhibitors, systemic antibiotics were associated with a reduction in grade 3–4 cutaneous adverse events, while pooled topical interventions significantly reduced grade 1–4 events. However, the effectiveness of individual topical agents, including urea, remains uncertain.

Related

  1. Community-Based Cardio-Oncology Model for Hypertension Management in Gynecologic Oncology Patients on VEGF Inhibitors
    Pragnya Tatikonda, Lalitha C. Medepalli, Christopher N. Cooper +5
    JACC Case ReportsPeer-reviewedCC BY-NC-ND 4.0Full textCardiovascular medicinePMC
  2. Operative management of abdominal bulge following deep inferior epigastric perforator flap breast reconstruction: a systematic review of repair strategies and outcomes
    Raj Saini, Akshay Soni, Felicity Huang +2
    Gland SurgeryPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Translational design of multifunctional novasomes for theranostic-driven precision therapy of cutaneous oncology.
    Md Azhar, Rishabha Malviya, Phool Chandra +4
    Journal of biological engineeringPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMCPMC
  4. Recent Advances in Nanomedicine-Enhanced Photodynamic Therapy in Cutaneous Oncology: Melanoma-Dominant Evidence for Immunogenic Cell Death and Photoimmunotherapy.
    Dorota Bartusik-Aebisher, Izabella Wilk, David Aebisher
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Outcomes and organ protection effects of perioperative precision venous access management strategies in patients undergoing complex hepatobiliary, pancreatic, splenic and abdominal great vascular surgery: a systematic review and meta-analysis.
    Jun Zhu, Sufang Fang
    BMC surgeryPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{arok2026management,
  title = {{Management Strategies for Cutaneous Adverse Events Caused by Kinase Inhibitors in Oncology: A Systematic Review and Meta-Analysis}},
  author = {Renáta Árok and Fanni Adél Meznerics and Andrea Lancz and Anna Sára Lengyel and Anna Walter and Péter Hegyi and András Bánvölgyi and Norbert Kiss},
  journal = {Cancers},
  year = {2026},
  month = oct,
  doi = {10.3390/cancers18203263},
  url = {https://www.mdpi.com/2072-6694/18/20/3263},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Management Strategies for Cutaneous Adverse Events Caused by Kinase Inhibitors in Oncology: A Systematic Review and Meta-Analysis
AU  - Renáta Árok
AU  - Fanni Adél Meznerics
AU  - Andrea Lancz
AU  - Anna Sára Lengyel
AU  - Anna Walter
AU  - Péter Hegyi
AU  - András Bánvölgyi
AU  - Norbert Kiss
PY  - 2026
DA  - 2026/10/01
JO  - Cancers
DO  - 10.3390/cancers18203263
UR  - https://www.mdpi.com/2072-6694/18/20/3263
AB  - Background: The use of targeted therapies in oncology has increased significantly, but associated cutaneous adverse events often impair quality of life and adherence. Despite numerous available interventions, there is no unified protocol, and many patients discontinue therapy due to adverse events. This systematic review and meta-analysis aimed to evaluate preventive and reactive interventions for cutaneous adverse events in adult cancer patients receiving kinase inhibitors. Methods: A search was performed in MEDLINE (via PubMed), EMBASE, and CENTRAL (The Cochrane Central Register of Controlled Trials), using predefined search terms. Outcomes were incidence, severity of cutaneous adverse events (grades 1–4 and 3–4), quality of life and adherence to oncologic therapy. Results: After screening 35,072 records, 9 studies (1853 patients, per protocol) met the inclusion criteria for the meta-analysis, while 52 were included in the systematic review. Preventive topical agents significantly reduced the incidence of grade 1–4 cutaneous adverse events (OR, 0.55; 95% CI, 0.38–0.80; p = 0.012; I2 = 16%), whereas systemic interventions showed no significant benefit in this category. Conversely, for grade 3–4 events, systemic interventions were associated with a significantly reduced incidence (OR, 0.24; 95% CI, 0.14–0.41; p = 0.002, I2 = 0%), while topical agents had no significant effect. For reactive interventions, no consistent evidence of effectiveness was found, with high heterogeneity and a limited number of studies. Conclusions: In patients receiving kinase inhibitors, systemic antibiotics were associated with a reduction in grade 3–4 cutaneous adverse events, while pooled topical interventions significantly reduced grade 1–4 events. However, the effectiveness of individual topical agents, including urea, remains uncertain.
SN  - 2072-6694
ER  -